Nina Buchtele

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Topics

Acute Respiratory Distress Syndrome

Extracorporeal Membrane Oxygenation

Placebo Controlled

Top Venues

ASAIO journal (American Society for Artificial Internal Organs : 1992)

Medizinische Klinik, Intensivmedizin und Notfallmedizin

British journal of clinical pharmacology

Clinical epidemiology

This page only lists publications with an associated author ORCID identifier.

Publications

Bernhard Nagler, Nina Buchtele, Alexander Hermann, Oliver Robak, Andja Bojic, Peter Schellongowski, Thomas Staudinger
Comparison of Weaning Strategies in Patients Receiving Venovenous Extracorporeal Membrane Oxygenation: An Exploratory Retrospective Study. ASAIO journal (American Society for Artificial Internal Organs : 1992) (2024)
Nina Buchtele, Hanna Knaus, Peter Schellongowski
[Side effects of immune checkpoint inhibitor therapy : What intensive care specialists need to know]. Medizinische Klinik, Intensivmedizin und Notfallmedizin (2023)
Bernhard Nagler, Andreas Gleiss, Lisa Füreder, Nina Buchtele, Alexander Hermann, Andja Bojic, Peter Schellongowski, Thomas Staudinger, Oliver Robak
Comparison of Hemostatic Changes in Pump-driven Extracorporeal Carbon Dioxide Removal and Venovenous Extracorporeal Membrane Oxygenation. ASAIO journal (American Society for Artificial Internal Organs : 1992) 68 (11) (2022)
Nina Buchtele, Michael Schwameis, Dominik Roth, Franz Schwameis, Felix Kraft, Roman Ullrich, Jakob Mühlbacher, Roberta Laggner, Gunnar Gamper, Georg Semmler, Christian Schoergenhofer, Thomas Staudinger, Harald Herkner
Applicability of Vasopressor Trials in Adult Critical Care: A Prospective Multicentre Meta-Epidemiologic Cohort Study. Clinical epidemiology 14 (2022)
Nina Buchtele, Michael Schwameis, Christian Schoergenhofer, Ulla Derhaschnig, Christa Firbas, Rudolf Karch, Darrell Nix, Roman Schenk, Bernd Jilma
Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose-escalating trial. British journal of clinical pharmacology 86 (5) (2020)